Srikripa Devarakonda
Stock Analyst at Truist Securities
(2.13)
# 2,815
Out of 4,761 analysts
57
Total ratings
35.71%
Success rate
-0.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $220 → $210 | $140.64 | +49.32% | 3 | Feb 13, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,029 → $1,038 | $873.68 | +18.81% | 4 | Feb 3, 2025 | |
| ABBV AbbVie | Maintains: Buy | $211 → $217 | $202.08 | +7.38% | 3 | Feb 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,126 → $1,004 | $700.33 | +43.36% | 5 | Jan 8, 2025 | |
| KROS Keros Therapeutics | Maintains: Buy | $100 → $43 | $11.02 | +290.20% | 4 | Dec 23, 2024 | |
| PFE Pfizer | Maintains: Buy | $36 → $32 | $26.30 | +21.67% | 1 | Dec 18, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $33 → $50 | $27.07 | +84.71% | 6 | Nov 27, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $36 → $45 | $37.70 | +19.36% | 4 | Nov 25, 2024 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $54 → $53 | $36.81 | +43.98% | 3 | Nov 1, 2024 | |
| BMEA Biomea Fusion | Upgrades: Buy | $54 | $3.46 | +1,460.69% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $83 → $74 | $72.11 | +2.62% | 8 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $38.75 | +54.84% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $5.68 | +164.08% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.87 | +113.40% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $70 | $50.26 | +39.28% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $60 | $1.04 | +5,669.23% | 2 | Aug 11, 2023 |
Biogen
Feb 13, 2025
Maintains: Buy
Price Target: $220 → $210
Current: $140.64
Upside: +49.32%
Eli Lilly and Company
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $873.68
Upside: +18.81%
AbbVie
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $202.08
Upside: +7.38%
Regeneron Pharmaceuticals
Jan 8, 2025
Maintains: Buy
Price Target: $1,126 → $1,004
Current: $700.33
Upside: +43.36%
Keros Therapeutics
Dec 23, 2024
Maintains: Buy
Price Target: $100 → $43
Current: $11.02
Upside: +290.20%
Pfizer
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $26.30
Upside: +21.67%
Edgewise Therapeutics
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $27.07
Upside: +84.71%
Scholar Rock Holding
Nov 25, 2024
Maintains: Buy
Price Target: $36 → $45
Current: $37.70
Upside: +19.36%
Kymera Therapeutics
Nov 1, 2024
Reiterates: Buy
Price Target: $54 → $53
Current: $36.81
Upside: +43.98%
Biomea Fusion
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $3.46
Upside: +1,460.69%
Sep 18, 2024
Downgrades: Hold
Price Target: $83 → $74
Current: $72.11
Upside: +2.62%
Sep 9, 2024
Initiates: Buy
Price Target: $60
Current: $38.75
Upside: +54.84%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $5.68
Upside: +164.08%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $16.87
Upside: +113.40%
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $50.26
Upside: +39.28%
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $1.04
Upside: +5,669.23%